AVERT Shock Trial Overcomes Barriers to Trauma Research, Shows Promise for Vasopressin Supplementation
September 12, 2019
September 12, 2019
SAN ANTONIO, Texas, Sept. 12 -- The National Trauma Institute issued the following information:
In the August issue of JAMA Surgery, Dr. Carrie A. Sims, et al. published the results of their randomized clinical trial that studied whether low-dose arginine vasopressin supplementation decreases the need for blood transfusions among trauma patients in hemorrhagic shock (AVERT Shock Trial). Significantly, they found vasopressin supplementation is associated with a decrease of 1.4 liters . . .
In the August issue of JAMA Surgery, Dr. Carrie A. Sims, et al. published the results of their randomized clinical trial that studied whether low-dose arginine vasopressin supplementation decreases the need for blood transfusions among trauma patients in hemorrhagic shock (AVERT Shock Trial). Significantly, they found vasopressin supplementation is associated with a decrease of 1.4 liters . . .